Auna S.A. has announced its financial results for the third quarter of 2026, showcasing a 10% revenue growth year-over-year. The company, a leader in healthcare services in Latin America, continues to navigate challenges in profitability, particularly in Colombia and Peru. Despite these pressures, Auna's strong cash generation supports its ongoing projects and strategic initiatives.

Founded in Luxembourg, Auna S.A. operates primarily in the healthcare sector, classified under the SIC code 8011, which pertains to services related to offices and clinics of doctors of medicine. The company trades on the New York Stock Exchange under the ticker symbol AUNA. Auna has been active in filing with the SEC, with its most recent filing dated November 17, 2026, detailing its financial performance for the third quarter.

According to the latest filing, Auna reported a 10% increase in FX-neutral revenue, reaching S/1,325 million for the quarter. This growth was attributed to improved performance across all markets, with Mexico leading the way with a 16% increase in revenue. However, the company faced profitability challenges, particularly in Colombia, where Adjusted EBITDA declined by 30% due to increased medical costs and regulatory pressures.

The filing states, "Adjusted EBITDA was S/231 million, decreasing 4.6% FXN while remaining flat as reported." Auna's cash flow generation has remained robust, with net cash from operating activities increasing by 62% year-over-year to S/713 million, and free cash flow rising by 95% to S/626 million. This strong cash generation has allowed Auna to improve its leverage ratio to 3.5x, moving closer to its medium-term target of below 3.0x.

The implications of Auna's financial results are significant for various stakeholders. Investors will be keenly observing the company's ability to manage profitability pressures while maintaining strong revenue growth. Auna's performance could impact competitors in the healthcare services sector, particularly those operating in similar markets like Colombia and Peru. The filing does not mention specific competitors.

Looking ahead, Auna has reaffirmed its full-year revenue guidance, expecting FX-neutral growth within the range of 10% to 14%. However, the company has revised its Adjusted EBITDA outlook, now anticipating that it will remain broadly stable or slightly down year-over-year due to the challenges faced in Colombia. Auna is committed to enhancing its operational efficiency and profitability across its markets.

In addition to its financial results, Auna highlighted the commencement of construction for the Centro Ambulatorio Trecca, a public-private partnership project in Peru. This facility is expected to significantly expand Auna's healthcare capacity in metropolitan Lima, serving approximately six million EsSalud-insured residents and supporting more than three million patient visits annually once operational.

Auna's strategic focus on capital-efficient growth opportunities and disciplined execution remains a priority as the company aims to strengthen its financial performance and create long-term shareholder value.